Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Advanced or Metastatic Dermatofibrosarcoma Protuberans
NCT00084630Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2004
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in dermatofibrosarcoma protuberans (DFSP), sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate at 5 years, Progression-Free Survival at 1 year and 2 more. Started May 2004; status: completed.
02
Drugs
03
Conditions
dermatofibrosarcoma protuberans (DFSP)
Beyond the preview
Go deeper on NCT00084630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00084630.